<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d87968c8-df9c-4a7b-9221-6dd0871214c6"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use MS CONTIN<sup>®</sup> safely and effectively. See full prescribing information for MS CONTIN. <br/>
      <br/>MS CONTIN<sup>®</sup> (morphine sulfate extended-release tablets), for oral use CII <br/>Initial U.S. Approval: 1941</title>
   <effectiveTime value="20250318"/>
   <setId root="c354b3bf-86c0-4bb8-8b1f-be2164942698"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="831928986" root="1.3.6.1.4.1.519.1"/>
            <name>Rhodes Pharmaceuticals L.P.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="567d7066-f22b-4d6a-9edc-3e6633e1cf0c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20231227"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42858-515" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MS Contin</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>morphine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="15" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="X3P646A2J0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>morphine sulfate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="76I7G6D29C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>morphine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2DMT128M1S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>cetostearyl alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8136Y38GY5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydroxyethyl cellulose (140 MPA.S at 5%)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polyethylene glycol, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C Blue No. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose, unspecified form</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="42858-515-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20170515"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019516" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170515"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PF;M15</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42858-631" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MS Contin</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>morphine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="30" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="X3P646A2J0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>morphine sulfate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="76I7G6D29C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>morphine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2DMT128M1S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>cetostearyl alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8136Y38GY5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydroxyethyl cellulose (140 MPA.S at 5%)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polyethylene glycol, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ECW0LZ41X8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C Red No. 7</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C Blue No. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose, unspecified form</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="42858-631-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20170515"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019516" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170515"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PURPLE" xsi:type="CE">
                              <originalText>Lavender</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PF;M30</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42858-760" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MS Contin</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>morphine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="60" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="X3P646A2J0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>morphine sulfate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="76I7G6D29C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>morphine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2DMT128M1S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>cetostearyl alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8136Y38GY5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydroxyethyl cellulose (140 MPA.S at 5%)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polyethylene glycol, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S42T2808B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C Red No. 30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C Yellow No. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydroxypropyl cellulose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose, unspecified form</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="42858-760-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20170515"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019516" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170515"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PF;M60</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42858-799" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MS Contin</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>morphine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="X3P646A2J0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>morphine sulfate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="76I7G6D29C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>morphine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2DMT128M1S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>cetostearyl alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8136Y38GY5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydroxyethyl cellulose (140 MPA.S at 5%)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polyethylene glycol, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferrosoferric oxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="42858-799-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20170515"/>
                                    <high value="20250304"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019516" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20170515"/>
                              <high value="20250304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48324" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAY" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PF;100</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42858-900" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MS Contin</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>morphine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="X3P646A2J0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>morphine sulfate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="76I7G6D29C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>morphine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2DMT128M1S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>cetostearyl alcohol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8136Y38GY5" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydroxyethyl cellulose (140 MPA.S at 5%)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polyethylene glycol, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C Yellow No. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C Blue No. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydroxypropyl cellulose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="42858-900-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20170515"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019516" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170515"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GREEN" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>capsule-shaped</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PF;M;200</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="d2ae122b-42f1-4d67-a94e-9147d116d9e8"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MS CONTIN</content>
               </title>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MS CONTIN</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning</content>.</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">MS CONTIN exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. (<linkHtml href="#S5.1">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of MS CONTIN are essential. Instruct patients to swallow MS CONTIN tablets whole to avoid exposure to a potentially fatal dose of morphine. (<linkHtml href="#S5.2">5.2</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Accidental ingestion of MS CONTIN, especially by children, can result in a fatal overdose of morphine. (<linkHtml href="#S5.2">5.2</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (<linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S7">7</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (<linkHtml href="#S5.4">5.4</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Healthcare providers are strongly encouraged to complete a REMS compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (<linkHtml href="#S5.5">5.5</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="dbcf147b-0adc-415b-acb1-34ef995b14f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold underline">Addiction, Abuse, and Misuse</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">Because the use of MS CONTIN exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="26fb88f8-6636-43fa-a5ec-b871a4280589"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold underline">Life-Threatening Respiratory Depression</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">Serious, life-threatening, or fatal respiratory depression may occur with use of MS CONTIN, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of MS CONTIN are essential. Instruct patients to swallow MS CONTIN tablets whole; crushing, chewing, or dissolving MS CONTIN tablets can cause rapid release and absorption of a potentially fatal dose of morphine. <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a2ed9f4e-e38c-4547-8cfb-e91be604f340"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold underline">Accidental Ingestion</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">Accidental ingestion of even one dose of MS CONTIN, especially by children, can result in a fatal overdose of morphine <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1cc76aab-404e-4fa9-9291-85d7c8002e29"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold underline">Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of MS CONTIN and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate <content styleCode="italics">[</content>see <content styleCode="italics">
                                    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d68b0ad4-b310-479c-96d4-4dfb77e67974"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold underline">Neonatal Opioid Withdrawal Syndrome (NOWS)</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="17805823-4a2c-4327-b360-90fc58bad785"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold underline">Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">
                              <content styleCode="bold">Healthcare providers are strongly encouraged to complete a REMS-compliant education program, and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="0dde950b-c389-40c7-bc12-5ccb66612860"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="70%" align="left" valign="top"/>
                           <col width="30%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <linkHtml href="#BOX">Boxed Warning</linkHtml>
                                 </td>
                                 <td>12/2023</td>
                              </tr>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#S1">1</linkHtml>)</td>
                                 <td>12/2023</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4</linkHtml>)</td>
                                 <td>12/2023</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.6">5.6</linkHtml>)</td>
                                 <td>12/2023</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="89aa8ffd-3e8d-4999-be28-e8b25b989532"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">MS CONTIN is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>MS CONTIN is an opioid agonist indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content> (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations, reserve MS CONTIN for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</item>
                           <item>MS CONTIN is not indicated as an as-needed (prn) analgesic.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="c9371d31-ebe0-4f8f-9712-06a14c95091a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="xmChange">Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended- release/long-acting opioid formulations <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>, reserve MS CONTIN for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.</content>
                           </item>
                           <item>MS CONTIN is not indicated as an as-needed (prn) analgesic.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="83a99e09-6cac-412c-b929-01e847bee4dd"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>MS CONTIN should be prescribed only by healthcare providers who are knowledgeable about the use of extended-release/long-acting opioids and how to mitigate the associated risks. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>MS CONTIN 100 mg and 200 mg tablets, a single dose greater than 60 mg, or a total daily dose greater than 120 mg, are only for use in patients in whom tolerance to an opioid of comparable potency has been established. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg of morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg of oral oxycodone per day, 8 mg of oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher doses of MS CONTIN for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. (<linkHtml href="#S2">2</linkHtml>, <linkHtml href="#S5">5</linkHtml>)</item>
                           <item>Initiate the dosing regimen for each patient individually, taking into account the patient's underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse. (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with MS CONTIN. Consider this risk when selecting an initial dose and when making dose adjustments. (<linkHtml href="#S2">2</linkHtml>, <linkHtml href="#S5">5</linkHtml>)</item>
                           <item>Discuss availability of naloxone with the patient and caregiver and assess each patient's need for access to naloxone, both when initiating and renewing treatment with MS CONTIN. Consider prescribing naloxone based on the patient's risk factors for overdose. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Instruct patients to swallow MS CONTIN tablets intact and not to cut, break, chew, crush, or dissolve MS CONTIN (risk of potentially fatal dose) (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>For opioid-naïve and opioid non-tolerant patients, initiate with 15 mg tablets orally every 8 to 12 hours. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>Do not abruptly discontinue MS CONTIN in a physically dependent patient because rapid discontinuation of opioid analgesics has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. (<linkHtml href="#S2.5">2.5</linkHtml>, <linkHtml href="#S5.14">5.14</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="79591f79-661a-4c08-9851-49c69a13421f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Dosage and Administration Instructions</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>MS CONTIN should be prescribed by healthcare professionals who are knowledgeable about the use of extended-release/long-acting opioids and how to mitigate the associated risks.</item>
                           <item>MS CONTIN 100 mg and 200 mg tablets, a single dose greater than 60 mg, or a total daily dose greater than 120 mg, are only for use in patients in whom tolerance to an opioid of comparable potency has been established. Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone daily, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.</item>
                           <item>
                              <content styleCode="xmChange">Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals <content styleCode="italics">[see <linkHtml href="#S5">Warnings and Precautions (5)</linkHtml>].</content> Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of MS CONTIN for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Initiate the dosing regimen for each patient individually, taking into account the patient's underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                              </content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with MS CONTIN. Consider this risk when selecting an initial dose and when making dose adjustments <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                              </content>
                           </item>
                           <item>Instruct patients to swallow MS CONTIN tablets whole. Crushing, chewing, or dissolving MS CONTIN tablets will result in uncontrolled delivery of morphine and can lead to overdose or death <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                           <item>MS CONTIN is administered orally once every 8 or 12 hours.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="1df31d07-b9da-4e35-aa80-b7165b5196f8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose</title>
                     <text>
                        <paragraph>Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with MS CONTIN <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program).</paragraph>
                        <paragraph>Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="ec425229-82bb-4c4f-ad8e-74870d4a1435"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Initial Dosage</title>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="cf0862b1-6cf5-483f-99eb-438749642446"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Use of MS CONTIN as the First Opioid Analgesic (opioid-naïve patients)</content>
                              </paragraph>
                              <paragraph>Initiate treatment with MS CONTIN at a dose of 15 mg tablets orally every 8 or 12 hours.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a05ead77-79eb-468c-ba9d-db810c7fd2f8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Use of MS CONTIN in Patients who are not Opioid Tolerant (opioid non-tolerant patients)</content>
                              </paragraph>
                              <paragraph>The starting dose for patients who are not opioid tolerant is MS CONTIN 15 mg orally every 12 hours.</paragraph>
                              <paragraph>Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f1954156-79e7-4e98-98f1-c6045a718619"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Conversion from Other Oral Morphine to MS CONTIN</content>
                              </paragraph>
                              <paragraph>Patients receiving other oral morphine formulations may be converted to MS CONTIN by administering one-half of the patient's 24-hour requirement as MS CONTIN on an every-12-hour schedule or by administering one-third of the patient's daily requirement as MS CONTIN on an every-8-hour schedule.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2e4609b1-87ba-42f6-b57d-334644c4a98d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Conversion from Other Opioids to MS CONTIN</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">When MS CONTIN therapy is initiated, discontinue all other opioid analgesics other than those used on an as needed basis for breakthrough pain when appropriate.</content>
                              </paragraph>
                              <paragraph>There are no established conversion ratios for conversion from other opioids to MS CONTIN defined by clinical trials. Initiate dosing using MS CONTIN 15 mg orally every 8 to 12 hours.</paragraph>
                              <paragraph>It is safer to underestimate a patient's 24-hour oral morphine dosage and provide rescue medication (e.g., immediate-release opioid) than to overestimate the 24-hour oral morphine dosage and manage an adverse reaction due to an overdose. While useful tables of opioid equivalents are readily available, there is inter-patient variability in the potency of opioid drugs and opioid formulations. Close observation and frequent titration are warranted until pain management is stable on the new opioid. Monitor patients for signs and symptoms of opioid withdrawal and for signs of oversedation/toxicity after converting patients to MS CONTIN.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="417a910e-ad37-45d6-a63d-1efaf0c8ef2e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Conversion from Parenteral Morphine or Other Opioids (Parenteral or Oral) to MS CONTIN</content>
                              </paragraph>
                              <paragraph>When converting from parenteral morphine or other non-morphine opioids (parenteral or oral) to MS CONTIN, consider the following general points:</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                           <component>
                              <section>
                                 <id root="eeae32d7-6120-4bc1-8bdc-22a1286c0735"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Parenteral to oral morphine ratio:</content> Between 2 to 6 mg of oral morphine may be required to provide analgesia equivalent to 1 mg of parenteral morphine. Typically, a dose of morphine that is approximately three times the previous daily parenteral morphine requirement is sufficient.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="19c90384-3f55-44bc-a9e3-52fc43efd9cd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Other parenteral or oral non-morphine opioids to oral morphine ratios:</content> Specific recommendations are not available because of a lack of systematic evidence for these types of analgesic substitutions. Published relative potency data are available, but such ratios are approximations. In general, begin with half of the estimated daily morphine requirement as the initial dose, managing inadequate analgesia by supplementation with immediate-release morphine.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0d8658ca-ec63-4dc9-b573-dbfc2f9ba386"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Conversion from Methadone to MS CONTIN</content>
                              </paragraph>
                              <paragraph>Regular evaluation is of particular importance when converting methadone to other opioid agonists. The ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="03333e03-a549-4a32-a788-3ad78472a013"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Titration and Maintenance of Therapy</title>
                     <text>
                        <paragraph>Individually titrate MS CONTIN to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving MS CONTIN to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.14">5.14)</linkHtml>]</content>. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During use of opioid therapy for an extended period of time, periodically reassess the continued need for the use of opioid analgesics.</paragraph>
                        <paragraph>Patients who experience breakthrough pain may require a dosage adjustment of MS CONTIN, or may need rescue medication with an appropriate dose of an immediate-release analgesic.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing the MS CONTIN dosage. If after increasing the dosage, unacceptable opioid- related adverse reactions are observed (including an increase in pain after a dosage increase), consider reducing the dosage <content styleCode="italics">[see <linkHtml href="#S5">Warnings and Precautions (5)</linkHtml>].</content> Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.</content>
                        </paragraph>
                        <paragraph>Because steady-state plasma concentrations are approximated in 1 day, MS CONTIN dosage adjustments may be done every 1 to 2 days.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="53a3191f-b334-46c0-b5ee-230da725d392"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Modifications with Concomitant Use of Central Nervous System Depressants</title>
                     <text>
                        <paragraph>If the patient is currently taking a central nervous system (CNS) depressant and the decision is made to begin MS CONTIN, start with the lowest possible dose, 15 mg every 12 hours, monitor patients for signs of respiratory depression, sedation, and hypotension, and consider using a lower dosage of the concomitant CNS depressant <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="a55e8dbb-8dd8-4cda-aa60-a288b3b003e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Safe Reduction or Discontinuation of MS CONTIN</title>
                     <text>
                        <paragraph>Do not abruptly discontinue MS CONTIN in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.</paragraph>
                        <paragraph>When a decision has been made to decrease the dose or discontinue therapy in an opioid dependent patient taking MS CONTIN, there are a variety of factors that should be considered, including the total daily dose of opioid (including MS CONTIN) the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate, and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with co-morbid pain and substance use disorders may benefit from referral to a specialist.</paragraph>
                        <paragraph>There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on MS CONTIN who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.</paragraph>
                        <paragraph>It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, evaluate patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.</paragraph>
                        <paragraph>When managing patients taking opioid analgesics, particularly those who have been treated for an extended period of time and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic <content styleCode="italics">[see <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>, <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="4862486b-5dc2-478d-958c-8363764857bf"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="disc">
                     <item>MS CONTIN<sup>®</sup> (morphine sulfate extended-release tablets) 15 mg Round, blue-colored, film-coated tablets bearing the symbol PF on one side and M 15 on the other</item>
                     <item>MS CONTIN<sup>®</sup> (morphine sulfate extended-release tablets) 30 mg<br/>Round, lavender-colored, film-coated tablets bearing the symbol PF on one side and M 30 on the other</item>
                     <item>MS CONTIN<sup>®</sup> (morphine sulfate extended-release tablets) 60 mg<br/>Round, orange-colored, film-coated tablets bearing the symbol PF on one side and M 60 on the other</item>
                     <item>MS CONTIN<sup>®</sup> (morphine sulfate extended-release tablets) 100 mg<br/>Round, gray-colored, film-coated tablets bearing the symbol PF on one side and 100 on the other</item>
                     <item>MS CONTIN<sup>®</sup> (morphine sulfate extended-release tablets) 200 mg<br/>Capsule-shaped, green-colored, film-coated tablets bearing the symbol PF on one side and M 200 on the other</item>
                  </list>
               </text>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Extended-release tablets: 15 mg, 30 mg, 60 mg, 100 mg, 200 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="70c004c7-f5d6-4718-9e9e-299dc1210026"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>MS CONTIN is contraindicated in patients with:</paragraph>
                  <list>
                     <item>Significant respiratory depression <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</item>
                     <item>Known or suspected gastrointestinal obstruction, including paralytic ileus <content styleCode="italics">[see <linkHtml href="#S5.12">Warnings and Precautions (5.12)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity (e.g., anaphylaxis) to morphine <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Significant respiratory depression (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Known or suspected gastrointestinal obstruction, including paralytic ileus (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Hypersensitivity to morphine (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="75f2e5b7-c3a2-41a4-b98d-45955932d1ee"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Opioid-Induced Hyperalgesia and Allodynia: Opioid-Induced</content>
                              <br/>Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. If OIH is suspected, carefully consider appropriately decreasing the dose of the current opioid analgesic, or opioid rotation. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</content>: Regularly evaluate, particularly during initiation and titration. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Adrenal Insufficiency</content>: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. (<linkHtml href="#S5.9">5.9</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Severe Hypotension</content>: Regularly evaluate during dosage initiation and titration. Avoid use in patients with circulatory shock. (<linkHtml href="#S5.10">5.10</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</content>: Monitor for sedation and respiratory depression. Avoid use of MS CONTIN in patients with impaired consciousness or coma. (<linkHtml href="#S5.11">5.11</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="fc1c25cf-0b0b-428d-93d4-eeeed9769cc6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Addiction, Abuse, and Misuse</title>
                     <text>
                        <paragraph>MS CONTIN contains morphine, a Schedule II controlled substance. As an opioid, MS CONTIN exposes its users to the risks of addiction, abuse, and misuse. Because extended-release products such as MS CONTIN deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of morphine present <content styleCode="italics">[see <linkHtml href="#S9">Drug Abuse and Dependence (9)</linkHtml>]</content>.</paragraph>
                        <paragraph>Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed MS CONTIN. Addiction can occur at recommended doses and if the drug is misused or abused.</paragraph>
                        <paragraph>Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing MS CONTIN, and reassess all patients receiving MS CONTIN for development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as MS CONTIN, but use in such patients necessitates intensive counseling about the risks of proper use of MS CONTIN along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Abuse or misuse of MS CONTIN by crushing, chewing, snorting, or injecting the dissolved product will result in the uncontrolled delivery of morphine and can result in overdose and death <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>]</content>.</paragraph>
                        <paragraph>Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing MS CONTIN. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and proper disposal of unused drug<content styleCode="italics">.</content> Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="231cb0dd-99fc-4346-8819-7c995f9fdeed"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Life-Threatening Respiratory Depression</title>
                     <text>
                        <paragraph>Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>]</content>. Carbon dioxide (CO<sub>2</sub>) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</paragraph>
                        <paragraph>While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of MS CONTIN, the risk is greatest during the initiation of therapy or following a dosage increase.</paragraph>
                        <paragraph>To reduce the risk of respiratory depression, proper dosing and titration of MS CONTIN are essential <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content>. Overestimating the MS CONTIN dosage when converting patients from another opioid product can result in a fatal overdose with the first dose.</paragraph>
                        <paragraph>Accidental ingestion of even one dose of MS CONTIN, especially by children, can result in respiratory depression and death due to an overdose of morphine.</paragraph>
                        <paragraph>Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose.</paragraph>
                        <paragraph>Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep- related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="62f1baa9-0ac6-4342-a76a-fafcbae95c58"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose</content>
                              </paragraph>
                              <paragraph>Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with MS CONTIN. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program). Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help, even if naloxone is administered<content styleCode="italics">.</content>
                              </paragraph>
                              <paragraph>Consider prescribing naloxone, based on the patient's risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient.</paragraph>
                              <paragraph>Also consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose. If naloxone is prescribed, educate patients and caregivers on how to treat with naloxone <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>, <linkHtml href="#S10">Overdosage (10)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="da7de384-8711-4ccb-8257-d9d74e6d3684"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants</title>
                     <text>
                        <paragraph>Profound sedation, respiratory depression, coma, and death may result from the concomitant use of MS CONTIN with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non- benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.</paragraph>
                        <paragraph>Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                        <paragraph>If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use. In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation).</paragraph>
                        <paragraph>If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, <linkHtml href="#S10">Overdosage (10)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Advise both patients and caregivers about the risks of respiratory depression and sedation when MS CONTIN is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="92a48769-eaca-4b95-9adc-2165ce5052ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Neonatal Opioid Withdrawal Syndrome</title>
                     <text>
                        <paragraph>Use of MS CONTIN for an extended period of time during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for an extended period of time of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="2e7c474c-d6c5-4af0-bdd8-da23d5a4a488"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)</title>
                     <text>
                        <paragraph>To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to do all of the following:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Complete a REMS-compliant education program offered by an accredited provider of continuing education (CE) or another education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain.</item>
                           <item>Discuss the safe use, serious risks, and proper storage and disposal of opioid analgesics with patients and/or their caregivers every time these medicines are prescribed. The Patient Counseling Guide (PCG) can be obtained at this link: <content styleCode="underline">www.fda.gov/OpioidAnalgesicREMSPCG</content>.</item>
                           <item>Emphasize to patients and their caregivers the importance of reading the Medication Guide that they will receive from their pharmacist every time an opioid analgesic is dispensed to them.</item>
                           <item>Consider using other tools to improve patient, household, and community safety, such as patient- prescriber agreements that reinforce patient-prescriber responsibilities.</item>
                           <item>To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-800-503-0784, or log on to <content styleCode="underline">www.opioidanalgesicrems.com</content>. The FDA Blueprint can be found at <content styleCode="underline">www.fda.gov/OpioidAnalgesicREMSBlueprint</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="232cb3df-7b81-4f42-a12d-55a5bdf5c17f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Opioid-Induced Hyperalgesia and Allodynia</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. This condition differs from tolerance, which is the need for increasing doses of opioids to maintain a defined effect <content styleCode="italics">[see <linkHtml href="#S9.3">Dependence (9.3)</linkHtml>].</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Symptoms of OIH include (but may not be limited to) increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Cases of OIH have been reported, both with short-term and longer-term use of opioid analgesics. Though the mechanism of OIH is not fully understood, multiple biochemical pathways have been implicated. Medical literature suggests a strong biologic plausibility between opioid analgesics and OIH and allodynia. If a patient is suspected to be experiencing OIH, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation (safely switching the patient to a different opioid moiety) <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="b82b8a96-a3e3-4581-8d21-f2e6b0ee4c85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Risk of Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients</title>
                     <text>
                        <paragraph>The use of MS CONTIN in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="f981fd2a-073f-457f-a675-67836886d2e6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Patients with Chronic Pulmonary Disease</content>: MS CONTIN-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of MS CONTIN <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="87ee39cc-b90d-4136-bb25-20e3e0721e94"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elderly, Cachectic, or Debilitated Patients</content>: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>Regularly evaluate patients, particularly when initiating and titrating MS CONTIN and when MS CONTIN is given concomitantly with other drugs that depress respiration <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. Alternatively, consider the use of non-opioid analgesics in these patients.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="7ebf2f9e-611c-4d38-a0aa-e5e14c3b3391"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8	Interaction with Monoamine Oxidase Inhibitors</title>
                     <text>
                        <paragraph>Monoamine oxidase inhibitors (MAOIs) may potentiate the effects of morphine, including respiratory depression, coma, and confusion. MS CONTIN should not be used in patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="c0d3d651-d7aa-4a88-b005-d70214d77789"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9	Adrenal Insufficiency</title>
                     <text>
                        <paragraph>Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="3b56f933-4955-483c-a42b-a47f2160bb29"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10	Severe Hypotension</title>
                     <text>
                        <paragraph>MS CONTIN may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                        <paragraph>Regularly evaluate these patients for signs of hypotension after initiating or titrating the dosage of MS CONTIN. In patients with circulatory shock, MS CONTIN may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of MS CONTIN in patients with circulatory shock.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="18e76601-f086-4138-af45-1e3d006d6491"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11	Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness</title>
                     <text>
                        <paragraph>In patients who may be susceptible to the intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), MS CONTIN may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Regularly evaluate such patients for signs of sedation and respiratory depression, particularly when initiating therapy with MS CONTIN.</paragraph>
                        <paragraph>Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of MS CONTIN in patients with impaired consciousness or coma.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="0ecedeaf-05b4-459f-878f-e514fc633a73"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12	Risks of Use in Patients with Gastrointestinal Conditions</title>
                     <text>
                        <paragraph>MS CONTIN is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.</paragraph>
                        <paragraph>The morphine in MS CONTIN may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Regularly evaluate patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.13">
                     <id root="0c54e37c-1184-4cab-be57-7e98dd9b7a1a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13	Increased Risk of Seizures in Patients with Seizure Disorders</title>
                     <text>
                        <paragraph>The morphine in MS CONTIN may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Regularly evaluate patients with a history of seizure disorders for worsened seizure control during MS CONTIN therapy.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.14">
                     <id root="c58185fb-81e0-4996-9cb5-3dd981532cd4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14	Withdrawal</title>
                     <text>
                        <paragraph>Do not abruptly discontinue MS CONTIN in a patient physically dependent on opioids. When discontinuing MS CONTIN in a physically dependent patient, gradually taper the dosage. Rapid tapering of morphine in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who have received or are receiving a course of therapy with a full opioid agonist analgesic, including MS CONTIN. In these patients, mixed agonists/antagonist and partial agonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.15">
                     <id root="7d35c426-a9b0-4ee9-940e-cf0c24bc49da"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.15	Risks of Driving and Operating Machinery</title>
                     <text>
                        <paragraph>MS CONTIN may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of MS CONTIN and know how they will react to the medication.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="b7f160a0-ef0d-43b0-8787-9e22a1bac16d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described, or described in greater detail, in other sections:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Addiction, Abuse, and Misuse <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Life-Threatening Respiratory Depression <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Interactions with Benzodiazepine or Other CNS Depressants <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3</linkHtml>]</content>
                     </item>
                     <item>Neonatal Opioid Withdrawal Syndrome <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Opioid-Induced Hyperalgesia and Allodynia <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Adrenal Insufficiency <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                     <item>Severe Hypotension <content styleCode="italics">[see <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>]</content>
                     </item>
                     <item>Gastrointestinal Adverse Reactions <content styleCode="italics">[see <linkHtml href="#S5.12">Warnings and Precautions (5.12)</linkHtml>]</content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see <linkHtml href="#S5.13">Warnings and Precautions (5.13)</linkHtml>]</content>
                     </item>
                     <item>Withdrawal <content styleCode="italics">[see <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (&gt;10%): constipation, nausea, and sedation. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Rhodes Pharmaceuticals at 1-888-827-0616 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="83160864-cbfb-4819-a535-b57be4861f18"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>MS CONTIN may increase the risk of serious adverse reactions such as those observed with other opioid analgesics, including respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, or shock <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="07b85662-200e-43f6-a346-35593ab961f7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Most Frequently Observed Reactions</content>
                              </paragraph>
                              <paragraph>In clinical trials, the most common adverse reactions with MS CONTIN were constipation, dizziness, sedation, nausea, vomiting, sweating, dysphoria, and euphoric mood.</paragraph>
                              <paragraph>Some of these effects seem to be more prominent in ambulatory patients and in those not experiencing severe pain.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7683de1a-d758-4995-ab3b-af218e8ac522"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Less Frequently Observed Reactions</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cardiovascular disorders:</content> tachycardia, bradycardia, palpitations</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Eye disorders:</content> visual impairment, vision blurred, diplopia, miosis</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal disorders:</content> dry mouth, diarrhea, abdominal pain, constipation, dyspepsia</paragraph>
                              <paragraph>
                                 <content styleCode="italics">General disorders and administration site conditions:</content> chills, feeling abnormal, edema, edema peripheral, weakness</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hepatobiliary disorders:</content> biliary colic</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Metabolism and nutrition disorders:</content> anorexia</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Musculoskeletal and connective tissue disorders:</content> muscle rigidity, muscle twitching</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Nervous system disorders:</content> presyncope, syncope, headache, tremor, uncoordinated muscle movements, convulsion, intracranial pressure increased, taste alteration, paresthesia, nystagmus</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Psychiatric disorders:</content> agitation, mood altered, anxiety, depression, abnormal dreams, hallucination, disorientation, insomnia</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Renal and urinary disorders:</content> urinary retention, urinary hesitation, antidiuretic effects</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Reproductive system and breast disorders:</content> reduced libido and/or potency</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Respiratory, thoracic and mediastinal disorders:</content> laryngospasm</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Skin and subcutaneous tissue disorders:</content> pruritus, urticaria, rash</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Vascular disorders:</content> flushing, hypotension, hypertension</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="4d6054fb-1b3c-4901-a35c-7489902f1eea"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Post-Marketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of MS CONTIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Amenorrhea, asthenia, bronchospasm, confusional state<content styleCode="italics">,</content> drug hypersensitivity, fatigue, hyperalgesia, hypertonia, ileus, increased hepatic enzymes, intestinal obstruction, lethargy, malaise, pulmonary edema, thinking disturbances, somnolence, and vertigo<content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="f28c8dfb-08f0-48a1-8ef2-5b40e3c26ebc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Serotonin syndrome</content>: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3af71483-e5f8-4fbc-96cf-f3f08bc5717e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adrenal insufficiency</content>: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="bcb90818-e34f-4847-970d-78c6a6bd5fc7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Anaphylaxis</content>: Anaphylaxis has been reported with ingredients contained in MS CONTIN.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="916f292c-9edb-40a7-9f18-0ec1fe08cf21"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Androgen deficiency</content>: Cases of androgen deficiency have occurred with use of opioids for an extended period of time. <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0fa99242-0384-4978-b863-40593c837f97"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hyperalgesia and Allodynia</content>: Cases of hyperalgesia and allodynia have been reported with opioid therapy of any duration <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="47f1d804-56bd-4952-a6b6-58c2ed650055"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hypoglycemia: Cases of hypoglycemia have been reported in patients taking opioids. Most reports were in patients with at least one predisposing risk factor (e.g., diabetes).</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="057e0ea7-ecfa-4c1d-8588-9da8550e4831"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table 1 includes clinically significant drug interactions with MS CONTIN.</paragraph>
                  <table width="90%">
                     <caption>Table 1: Clinically Significant Drug Interactions with MS CONTIN</caption>
                     <col width="20%" align="right" valign="top"/>
                     <col width="80%" align="left" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" colspan="2">
                              <content styleCode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.5">2.5)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>]</content>.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Rrule">Benzodiazepines and other sedative hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" colspan="2">
                              <content styleCode="bold">Serotonergic Drugs</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue MS CONTIN if serotonin syndrome is suspected.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Rrule">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" colspan="2">
                              <content styleCode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>].</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Do not use MS CONTIN in patients taking MAOIs or within 14 days of stopping such treatment.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Rrule">phenelzine, tranylcypromine, linezolid</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" colspan="2">
                              <content styleCode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">May reduce the analgesic effect of MS CONTIN and/or precipitate withdrawal symptoms.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Avoid concomitant use.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Rrule">butorphanol, nalbuphine, pentazocine, buprenorphine</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" colspan="2">
                              <content styleCode="bold">Muscle Relaxants</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Because of respiratory depression may be greater than otherwise expected, decrease the dosage of MS CONTIN and/or the muscle relaxant as necessary. Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>].</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Examples</content>
                           </td>
                           <td styleCode="Rrule">Cyclobenzaprine, metaxalone</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" colspan="2">
                              <content styleCode="bold">Cimetidine</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">The concomitant use of cimetidine can potentiate morphine effects and increase risk of hypotension, respiratory depression, profound sedation, coma, and death.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Evaluate patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of MS CONTIN and/or cimetidine as necessary.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" colspan="2">
                              <content styleCode="bold">  Diuretics</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" colspan="2">
                              <content styleCode="bold">  Anticholinergic Drugs</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Evaluate patients for signs of urinary retention or reduced gastric motility when MS CONTIN is used concomitantly with anticholinergic drugs.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="left" colspan="2">
                              <content styleCode="bold">P-Glycoprotein (P-gp) Inhibitors</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">The concomitant use of PGP-inhibitors can increase the exposure to morphine by about two-fold and can increase risk of hypotension, respiratory depression, profound sedation, coma, and death.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Evaluate patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of MS CONTIN and/or the PGP- inhibitor as necessary.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <content styleCode="italics">Example:</content>
                           </td>
                           <td styleCode="Rrule">Quinidine</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Serotonergic Drugs</content>: Concomitant use may result in serotonin syndrome. Discontinue MS CONTIN if serotonin syndrome is suspected. (<linkHtml href="#S7">7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>: Avoid use with MS CONTIN because they may reduce analgesic effect of MS CONTIN or precipitate withdrawal symptoms. (<linkHtml href="#S5.14">5.14</linkHtml>, <linkHtml href="#S7">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="1d7c35ad-b399-419b-b309-d3d40f0195b0"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20231227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Pregnancy</content>: May cause fetal harm. (<linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Lactation</content>: Not recommended. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="de9f00bd-0d6a-456f-99b4-d4410edd0e38"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="bc69f369-ee56-46d3-b00b-f3a15f5457bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Risk Summary</content>
                              </paragraph>
                              <paragraph>Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal withdrawal syndrome <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>].</content> There are no available data with MS CONTIN in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Published studies with morphine use during pregnancy have not reported a clear association with morphine and major birth defects <content styleCode="italics">[see <linkHtml href="#human">Human Data</linkHtml>].</content> In published animal reproduction studies, morphine administered subcutaneously during the early gestational period produced neural tube defects (i.e., exencephaly and cranioschisis) at 5 and 16 times the human daily dose of 60 mg based on body surface area (HDD) in hamsters and mice, respectively, lower fetal body weight and increased incidence of abortion at 0.4 times the HDD in the rabbit, growth retardation at 6 times the HDD in the rat, and axial skeletal fusion and cryptorchidism at 16 times the HDD in the mouse. Administration of morphine sulfate to pregnant rats during organogenesis and through lactation resulted in cyanosis, hypothermia, decreased brain weights, pup mortality, decreased pup body weights, and adverse effects on reproductive tissues at 3 to 4 times the HDD; and long-term neurochemical changes in the brain of offspring which correlate with altered behavioral responses that persist through adulthood at exposures comparable to and less than the HDD [<content styleCode="italics">see <linkHtml href="#animal">Animal Data</linkHtml>
                                 </content>]. Based on animal data, advise pregnant women of the potential risk to a fetus.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="167b49c9-c2ae-4473-96ee-6bbe111bae14"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                           <component>
                              <section>
                                 <id root="16c743da-1fe5-4acf-b1ac-bb8ca197331e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Use of opioid analgesics for an extended period of time during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="1c2f0666-ffc1-46a7-b13a-27584a63c9b7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Labor or Delivery</content>
                                    </paragraph>
                                    <paragraph>Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid- induced respiratory depression in the neonate. MS CONTIN is not recommended for use in pregnant women during or immediately prior to labor, when use of shorter-acting analgesics or other analgesic techniques are more appropriate. Opioid analgesics, including MS CONTIN, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="a0e3168e-fb61-44da-a166-0237d040bd21"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                           <component>
                              <section ID="human">
                                 <id root="ff19147c-76a9-441f-8c28-5e81c53d4834"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>The results from a population-based prospective cohort, including 70 women exposed to morphine during the first trimester of pregnancy and 448 women exposed to morphine at any time during pregnancy, indicate no increased risk for congenital malformations. However, these studies cannot definitely establish the absence of any risk because of methodological limitations, including small sample size and non-randomized study design.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                           <component>
                              <section ID="animal">
                                 <id root="444af6be-8492-46e8-a47c-2409fa78b0a2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Formal reproductive and developmental toxicology studies for morphine have not been conducted. Exposure margins for the following published study reports are based on human daily dose of 60 mg morphine using a body surface area comparison (HDD).</paragraph>
                                    <paragraph>Neural tube defects (exencephaly and cranioschisis) were noted following subcutaneous administration of morphine sulfate (35 to 322 mg/kg) on Gestation Day 8 to pregnant hamsters (4.7 to 43.5 times the HDD). A no adverse effect level was not defined in this study and the findings cannot be clearly attributed to maternal toxicity. Neural tube defects (exencephaly), axial skeletal fusions, and cryptorchidism were reported following a single subcutaneous (SC) injection of morphine sulfate to pregnant mice (100 to 500 mg/kg) on Gestation Day 8 or 9 at 200 mg/kg or greater (16 times the HDD) and fetal resorption at 400 mg/kg or higher (32 times the HDD). No adverse effects were noted following 100 mg/kg morphine in this model (8 times the HDD). In one study, following continuous subcutaneous infusion of doses greater than or equal to 2.72 mg/kg to mice (0.2 times the HDD), exencephaly, hydronephrosis, intestinal hemorrhage, split supraoccipital, malformed sternebrae, and malformed xiphoid were noted. The effects were reduced with increasing daily dose; possibly due to rapid induction of tolerance under these infusion conditions. The clinical significance of this report is not clear.</paragraph>
                                    <paragraph>Decreased fetal weights were observed in pregnant rats treated with 20 mg/kg/day morphine sulfate (3.2 times the HDD) from Gestation Day 7 to 9. There was no evidence of malformations despite maternal toxicity (10% mortality). In a second rat study, decreased fetal weight and increased incidences of growth retardation were noted at 35 mg/kg/day (5.7 times the HDD) and there was a reduced number of fetuses at 70 mg/kg/day (11.4 times the HDD) when pregnant rats were treated with 10, 35, or 70 mg/kg/day morphine sulfate via continuous infusion from Gestation Day 5 to 20. There was no evidence of fetal malformations or maternal toxicity.</paragraph>
                                    <paragraph>An increased incidence of abortion was noted in a study in which pregnant rabbits were treated with 2.5 (0.8 times the HDD) to 10 mg/kg morphine sulfate via subcutaneous injection from Gestation Day 6 to 10. In a second study, decreased fetal body weights were reported following treatment of pregnant rabbits with increasing doses of morphine (10 to 50 mg/kg/day) during the pre-mating period and 50 mg/kg/day (16 times the HDD) throughout the gestation period. No overt malformations were reported in either publication; although only limited endpoints were evaluated.</paragraph>
                                    <paragraph>In published studies in rats, exposure to morphine during gestation and/or lactation periods is associated with: decreased pup viability at 12.5 mg/kg/day or greater (2 times the HDD); decreased pup body weights at 15 mg/kg/day or greater (2.4 times the HDD); decreased litter size, decreased absolute brain and cerebellar weights, cyanosis, and hypothermia at 20 mg/kg/day (3.2 times the HDD); alteration of behavioral responses (play, social-interaction) at 1 mg/kg/day or greater (0.2 times the HDD); alteration of maternal behaviors (e.g., decreased nursing and pup retrievals) in mice at 1 mg/kg or higher (0.08 times the HDD) and rats at 1.5 mg/kg/day or higher (0.2 times the HDD); and a host of behavioral abnormalities in the offspring of rats, including altered responsiveness to opioids at 4 mg/kg/day (0.7 times the HDD) or greater.</paragraph>
                                    <paragraph>Fetal and/or postnatal exposure to morphine in mice and rats has been shown to result in morphological changes in fetal and neonatal brain and neuronal cell loss, alteration of a number of neurotransmitter and neuromodulator systems, including opioid and non-opioid systems, and impairment in various learning and memory tests that appear to persist into adulthood. These studies were conducted with morphine treatment usually in the range of 4 to 20 mg/kg/day (0.7 to 3.2 times the HDD).</paragraph>
                                    <paragraph>Additionally, delayed sexual maturation and decreased sexual behaviors in female offspring at 20 mg/kg/day (3.2 times the HDD), and decreased plasma and testicular levels of luteinizing hormone and testosterone, decreased testes weights, seminiferous tubule shrinkage, germinal cell aplasia, and decreased spermatogenesis in male offspring were also observed at 20 mg/kg/day (3.2 times the HDD). Decreased litter size and viability were observed in the offspring of male rats that were intraperitoneally administered morphine sulfate for 1 day prior to mating at 25 mg/kg/day (4.1 times the HDD) and mated to untreated females. Decreased viability and body weight and/or movement deficits in both first- and second-generation offspring were reported when male mice were treated for 5 days with escalating doses of 120 to 240 mg/kg/day morphine sulfate (9.7 to 19.5 times the HDD) or when female mice treated with escalating doses of 60 to 240 mg/kg/day (4.9 to 19.5 times the HDD) followed by a 5-day treatment-free recovery period prior to mating. Similar multigenerational findings were also seen in female rats pre-gestationally treated with escalating doses of 10 to 22 mg/kg/day morphine (1.6 to 3.6 times the HDD).</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="ceb5339a-22f9-42e9-ae17-6f05a017cafc"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="b02fdacd-b85d-4fbd-ab42-6b93252a6431"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Morphine is present in breast milk. Published lactation studies report variable concentrations of morphine in breast milk with administration of immediate-release morphine to nursing mothers in the early postpartum period with a milk-to-plasma morphine AUC ratio of 2.5:1 measured in one lactation study. However, there is insufficient information to determine the effects of morphine on the breastfed infant and the effects of morphine on milk production. Lactation studies have not been conducted with extended –release morphine, including MS Contin. Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with MS CONTIN.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f1abedc0-f5a3-46f8-af8d-f44e3ea31921"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Monitor infants exposed to MS CONTIN through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="8dcf1cef-42db-4509-9e34-73574885e5e9"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="4c2dc785-ea73-48d9-ad38-ba4689376cb5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                              <paragraph>Use of opioids for an extended period of time may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>, <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>, <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]]</content>.</paragraph>
                              <paragraph>In published animal studies, morphine administration adversely effected fertility and reproductive endpoints in male rats and prolonged estrus cycle in female rats [<content styleCode="italics">see <linkHtml href="#S13">Nonclinical Toxicology (13)</linkHtml>
                                 </content>].</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="e6268856-c725-4d33-b721-718ae7e80fc9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness in pediatric patients below the age of 18 have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="24c41dc7-74f1-4fe1-ab08-921144b512cd"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>The pharmacokinetics of MS CONTIN have not been studied in elderly patients. Clinical studies of MS CONTIN did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</paragraph>
                        <paragraph>Elderly patients (aged 65 years or older) may have increased sensitivity to morphine. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of MS CONTIN slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                        <paragraph>Morphine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to regularly evaluate renal function.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="86707777-484e-4ea5-ac00-8f5c9b796f8d"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Morphine pharmacokinetics have been reported to be significantly altered in patients with cirrhosis. Start these patients with a lower than usual dosage of MS CONTIN and titrate slowly while regularly evaluating for signs of respiratory depression, sedation, and hypotension <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="67e9db3c-43d2-4a6c-be7a-2b0f1afefad7"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>Morphine pharmacokinetics are altered in patients with renal failure. Start these patients with a lower than usual dosage of MS CONTIN and titrate slowly while regularly evaluating for signs of respiratory depression, sedation, and hypotension <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S9">
               <id root="3a37025c-e04c-4eb5-be78-9f34ddfa0cd5"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20231227"/>
               <component>
                  <section ID="S9.1">
                     <id root="e776f790-8ea3-48e6-ba17-abb0ec5bc9db"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>MS CONTIN contains morphine, a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.2">
                     <id root="88c13a62-68ff-448f-bd5d-41f2438a166e"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>MS CONTIN contains morphine, a substance with a high potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed.</paragraph>
                        <paragraph>Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.</paragraph>
                        <paragraph>Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than to other activities and obligations), and possible tolerance or physical dependence.</paragraph>
                        <paragraph>Misuse and abuse of MS CONTIN increases risk of overdose, which may lead to central nervous system and respiratory depression, hypotension, seizures, and death. The risk is increased with concurrent abuse of MS CONTIN with alcohol and/or other CNS depressants. Abuse of and addiction to opioids in some individuals may not be accompanied by concurrent tolerance and symptoms of physical dependence. In addition, abuse of opioids can occur in the absence of addiction.</paragraph>
                        <paragraph>All patients treated with opioids require careful and frequent reevaluation for signs of misuse, abuse, and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Patients at high risk of MS CONTIN abuse include those with a history of prolonged use of any opioid, including products containing morphine, those with a history of drug or alcohol abuse, or those who use MS CONTIN in combination with other abused drugs.</paragraph>
                        <paragraph>"Drug-seeking" behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated "loss" of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other healthcare provider(s). "Doctor shopping" (visiting multiple prescribers to obtain additional prescriptions) is common among people who abuse drugs and people with substance use disorder. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.</paragraph>
                        <paragraph>MS CONTIN, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.</paragraph>
                        <paragraph>Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="716e125a-90ea-4a03-9a62-2147ce4dd91c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risks Specific to Abuse of MS CONTIN</content>
                              </paragraph>
                              <paragraph>Abuse of MS CONTIN poses a risk of overdose and death. This risk is increased with concurrent use of MS CONTIN with alcohol and/or other CNS depressants <content styleCode="italics">[see <linkHtml href="#S5.1">Warning and Precautions (5.1</linkHtml>, <linkHtml href="#s5.3">5.3)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content> Taking cut, broken, chewed, crushed, or dissolved MS CONTIN enhances drug release and increases the risk of overdose and death.</paragraph>
                              <paragraph>MS CONTIN is approved for oral use only.</paragraph>
                              <paragraph>Due to the presence of talc as one of the excipients in MS CONTIN, parenteral abuse can be expected to result in local tissue necrosis, infection, pulmonary granulomas, embolism and death, and increased risk of endocarditis and valvular heart injury.</paragraph>
                              <paragraph>Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S9.3">
                     <id root="089d5de2-d9b1-4664-a45e-cf0eea87f83e"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>Both tolerance and physical dependence can develop during use of opioid therapy.</paragraph>
                        <paragraph>Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).</paragraph>
                        <paragraph>Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.</paragraph>
                        <paragraph>Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity, (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.</paragraph>
                        <paragraph>Do not abruptly discontinue MS CONTIN in a patient physically dependent on opioids. Rapid tapering of MS CONTIN in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.</paragraph>
                        <paragraph>When discontinuing MS CONTIN, gradually taper the dosage using a patient-specific plan that considers the following: the dose of MS CONTIN the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [<content styleCode="italics">see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="c517a0da-ddc7-44ed-bfea-bc8c846cba89"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20231227"/>
               <component>
                  <section>
                     <id root="48a1760d-a8dd-403c-939f-6d879dbcaffe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Clinical Presentation</content>
                        </paragraph>
                        <paragraph>Acute overdosage with morphine can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, hypoglycemia, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="57431cec-dd54-4242-90bb-23dd176fb58b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Treatment of Overdose</content>
                        </paragraph>
                        <paragraph>In case of overdose, priorities are the re-establishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life support measures .</paragraph>
                        <paragraph>Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to morphine overdose, administer an opioid antagonist.</paragraph>
                        <paragraph>Because the duration of reversal would be expected to be less than the duration of action of morphine in MS CONTIN, carefully monitor the patient until spontaneous respiration is reliably reestablished. MS CONTIN will continue to release morphine and add to the morphine load for 24 to 48 hours or longer following ingestion, necessitating prolonged monitoring. If the response to opioid antagonists is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information.</paragraph>
                        <paragraph>In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="4a7834ba-321f-4d34-98dd-055a13c4ea53"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>MS CONTIN (morphine sulfate extended-release tablets) is for oral use and contains morphine sulfate, an opioid agonist.</paragraph>
                  <paragraph>Each tablet contains the following inactive ingredients common to all strengths: cetostearyl alcohol, hydroxyethyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, talc, and titanium dioxide.</paragraph>
                  <paragraph>The tablet strengths describe the amount of morphine per tablet as the pentahydrated sulfate salt (morphine sulfate).</paragraph>
                  <paragraph>The 15 mg tablets also contain: FD&amp;C Blue No. 2, lactose, polysorbate 80</paragraph>
                  <paragraph>The 30 mg tablets also contain: D&amp;C Red No. 7, FD&amp;C Blue No. 1, lactose, polysorbate 80</paragraph>
                  <paragraph>The 60 mg tablets also contain: D&amp;C Red No. 30, D&amp;C Yellow No. 10, hydroxypropyl cellulose, lactose</paragraph>
                  <paragraph>The 100 mg tablets also contain: black iron oxide</paragraph>
                  <paragraph>The 200 mg tablets also contain: D&amp;C Yellow No. 10, FD&amp;C Blue No. 1, hydroxypropyl cellulose</paragraph>
                  <paragraph>Morphine sulfate is an odorless, white, crystalline powder with a bitter taste. It has a solubility of 1 in 21 parts of water and 1 in 1000 parts of alcohol, but is practically insoluble in chloroform or ether. The octanol: water partition coefficient of morphine is 1.42 at physiologic pH and the pK<sub>b</sub> is 7.9 for the tertiary nitrogen (mostly ionized at pH 7.4). Its molecular weight is 758.83 and its structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
               </text>
               <effectiveTime value="20231227"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ms-contin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="49922f95-4958-4f87-9a3d-caa7e23c98dc"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20231227"/>
               <component>
                  <section ID="S12.1">
                     <id root="e7baaa3b-c91b-449b-b584-9be8c1246d8f"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Morphine is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.</paragraph>
                        <paragraph>The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="8e9feb1a-7d24-45f8-9226-684abe91030e"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="ece61d66-d13d-4d4d-a708-f0f1d9a97818"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">CNS Depressant/Alcohol Interaction</content>
                              </paragraph>
                              <paragraph>Additive pharmacodynamic effects may be expected when MS CONTIN is used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3b0c78c7-5547-403e-b5a9-6894ff2fa45e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Central Nervous System</content>
                              </paragraph>
                              <paragraph>Morphine produces respiratory depression by direct action on brainstem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brainstem respiratory centers to both increases in carbon dioxide tension and electrical stimulation.</paragraph>
                              <paragraph>Morphine causes miosis, even in total darkness. Pinpoint pupils are a sign of narcotic overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="53d31e71-a1b8-4a8c-9805-448960a8603d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Gastrointestinal Tract and Other Smooth Muscle</content>
                              </paragraph>
                              <paragraph>Morphine causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and in the duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm, resulting in constipation. Other opioid-induced effects may include reduction in biliary and pancreatic secretions, spasm of the sphincter of Oddi, and transient elevations in serum amylase.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="39105784-fe77-4e84-87c7-f6776855af32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Cardiovascular System</content>
                              </paragraph>
                              <paragraph>Morphine produces peripheral vasodilation which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="273281d7-bb3b-4997-bc6b-30e0753b990c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Endocrine System</content>
                              </paragraph>
                              <paragraph>Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reaction (6.2)</linkHtml>]</content>. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon.</paragraph>
                              <paragraph>Use of opioids for an extended period of time may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1eb6c9c8-8979-4339-a05f-33fd58ec470a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Immune System</content>
                              </paragraph>
                              <paragraph>Opioids have been shown to have a variety of effects on components of the immune system in in vitro and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3e864321-a84e-4201-8e7a-7fadbe14045a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Concentration-Efficacy Relationships</content>
                              </paragraph>
                              <paragraph>The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with opioid agonists. The minimum effective analgesic concentration of morphine for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome, and/or the development of analgesic tolerance <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="44faaf34-4d57-47c3-b6ff-54628d9f47cc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Concentration–Adverse Reaction Relationships</content>
                              </paragraph>
                              <paragraph>There is a relationship between increasing morphine plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="d8bface8-e7f3-4153-9d62-62ab3b0251e3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="853b5bd3-900b-4c71-9004-c96d842dd3cd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>MS CONTIN is an extended-release tablet containing morphine sulfate. Morphine is released from MS CONTIN somewhat more slowly than from immediate-release oral preparations. Following oral administration of a given dose of morphine, the amount ultimately absorbed is essentially the same whether the source is MS CONTIN or an immediate-release formulation. Because of pre- systemic elimination (i.e., metabolism in the gut wall and liver) only about 40% of the administered dose reaches the central compartment.</paragraph>
                              <paragraph>The oral bioavailability of morphine is approximately 20 to 40%. When MS CONTIN is given on a fixed dosing regimen, steady-state is achieved in about a day.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                           <component>
                              <section>
                                 <id root="90fefc4a-dbd2-428a-8594-8f75fb7a2400"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline italics">Food Effect</content>
                                    </paragraph>
                                    <paragraph>The effect of food upon the systemic bioavailability of MS CONTIN has not been systematically evaluated for all strengths. One study, conducted with the 30 mg MS CONTIN tablets, showed no significant differences in C<sub>max</sub> and AUC <sub>(0-24h)</sub> values, whether the tablet was taken while fasting or with a high-fat breakfast.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="328e9ecd-a7bc-4897-b62e-90d940399587"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Once absorbed, morphine is distributed to skeletal muscle, kidneys, liver, intestinal tract, lungs, spleen, and brain. Morphine also crosses placental membranes and has been found in breast milk. The volume of distribution (Vd) for morphine is approximately 3 to 4 liters per kilogram and morphine is 30 to 35% reversibly bound to plasma proteins.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0100d0fd-6b0f-46d1-b0c8-614b08260eab"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                           <component>
                              <section>
                                 <id root="227968a0-36ae-420a-b6d3-388d67491748"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>The major pathways of morphine metabolism include glucuronidation to produce metabolites including morphine-3-glucuronide, M3G (about 50%) and morphine-6-glucuronide, M6G (about 5 to 15%) and sulfation in the liver to produce morphine-3-etheral sulfate. A small fraction (less than 5%) of morphine is demethylated. M6G has been shown to have analgesic activity but crosses the blood-brain barrier poorly, while M3G has no significant analgesic activity.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="4833b66e-9bd6-44ec-abbe-2ca69b91bf88"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>The elimination of morphine occurs primarily as renal excretion of M3G and its effective half-life after intravenous administration is normally 2 to 4 hours. Approximately 10% of the dose is excreted unchanged in urine. In some studies involving longer periods of plasma sampling, a longer terminal half-life of about 15 hours was reported. A small amount of the glucuronide conjugate is excreted in the bile, and there is some minor enterohepatic recycling.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c2228684-3f61-4c6b-8945-73cb3c4c0ac6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                           <component>
                              <section>
                                 <id root="0f650abc-53d2-4636-96c3-4e42e057b9e6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Sex</content>
                                    </paragraph>
                                    <paragraph>A sex analysis of pharmacokinetic data from healthy subjects taking MS CONTIN indicated that morphine concentrations were similar in males and females.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="9c60e3be-0f29-48c6-a31e-6fdc8881cd71"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Race/Ethnicity</content>
                                    </paragraph>
                                    <paragraph>Chinese subjects given intravenous morphine had a higher clearance when compared to Caucasian subjects (1852 +/- 116 ml/min compared to 1495 +/- 80 ml/min).</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="0e389f20-657b-4a87-808d-74621d362ce0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Morphine pharmacokinetics are altered in patients with cirrhosis. Clearance was found to decrease with a corresponding increase in half-life. The M3G and M6G to morphine plasma AUC ratios also decreased in these patients, indicating diminished metabolic activity. Adequate studies of the pharmacokinetics of morphine in patients with severe hepatic impairment have not been conducted.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="15ef5b30-a707-40f3-91b4-28301a81d7e1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Morphine pharmacokinetics are altered in patients with renal failure. The AUC is increased, and clearance is decreased and the metabolites, M3G and M6G, may accumulate to much higher plasma levels in patients with renal failure as compared to patients with normal renal function. Adequate studies of the pharmacokinetics of morphine in patients with severe renal impairment have not been conducted.</paragraph>
                                 </text>
                                 <effectiveTime value="20231227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="4e1313e7-dc04-4233-8a3d-320533ea4b4f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20231227"/>
               <component>
                  <section ID="S13.1">
                     <id root="63e863fa-6697-480d-a365-09114a7c7cbc"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="2f87c129-66a6-403f-bcfa-105986813a9e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Long-term studies in animals to evaluate the carcinogenic potential of morphine have not been conducted.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3a0ca5a2-f9ed-492f-89d1-ce22fe33bc07"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>No formal studies to assess the mutagenic potential of morphine have been conducted. In the published literature, morphine was found to be mutagenic in vitro increasing DNA fragmentation in human T-cells. Morphine was reported to be mutagenic in the in vivo mouse micronucleus assay and positive for the induction of chromosomal aberrations in mouse spermatids and murine lymphocytes. Mechanistic studies suggest that the in vivo clastogenic effects reported with morphine in mice may be related to increases in glucocorticoid levels produced by morphine in this species. In contrast to the above positive findings, in vitro studies in the literature have also shown that morphine did not induce chromosomal aberrations in human leukocytes or translocations or lethal mutations in Drosophila.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3d80a281-e879-4395-a993-f6947d12d645"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>No formal nonclinical studies to assess the potential of morphine to impair fertility have been conducted. Several nonclinical studies from the literature have demonstrated adverse effects on male fertility in the rat from exposure to morphine. One study in which male rats were administered morphine sulfate subcutaneously prior to mating (up to 30 mg/kg twice daily) and during mating (20 mg/kg twice daily) with untreated females, a number of adverse reproductive effects including reduction in total pregnancies and higher incidence of pseudopregnancies at 20 mg/kg/day (3.2 times the HDD) were reported.</paragraph>
                              <paragraph>Studies from the literature have also reported changes in hormonal levels in male rats (i.e. testosterone, luteinizing hormone) following treatment with morphine at 10 mg/kg/day or greater (1.6 times the HDD).</paragraph>
                              <paragraph>Female rats that were administered morphine sulfate intraperitoneally prior to mating exhibited prolonged estrous cycles at 10 mg/kg/day (1.6 times the HDD).</paragraph>
                              <paragraph>Exposure of adolescent male rats to morphine has been associated with delayed sexual maturation and following mating to untreated females, smaller litters, increased pup mortality, and/or changes in reproductive endocrine status in adult male offspring have been reported (estimated 5 times the plasma levels at the HDD).</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="7b052082-9fb0-4b34-89b7-9eef47f4228b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>MS CONTIN<sup>®</sup> (morphine sulfate extended-release tablets) are supplied as follows:</paragraph>
                  <paragraph>
                     <content styleCode="bold">15 mg </content>- round, blue-colored, film-coated tablets bearing the symbol PF on one side and M 15 on the other.</paragraph>
                  <table width="60%" styleCode="Noautorules">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="right" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottles (opaque plastic) of 100 tablets…</td>
                           <td>
                              <content styleCode="bold">NDC</content> 42858-515-01</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">30 mg </content>- round, lavender-colored, film-coated tablets bearing the symbol PF on one side and M 30 on the other.</paragraph>
                  <table width="60%" styleCode="Noautorules">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="right" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottles (opaque plastic) of 100 tablets…</td>
                           <td>
                              <content styleCode="bold">NDC</content> 42858-631-01</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">60 mg </content>- round, orange-colored, film-coated tablets bearing the symbol PF on one side and M 60 on the other.</paragraph>
                  <table width="60%" styleCode="Noautorules">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="right" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottles (opaque plastic) of 100 tablets…</td>
                           <td>
                              <content styleCode="bold">NDC</content> 42858-760-01</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">100 mg </content>- round, gray-colored, film-coated tablets bearing the symbol PF on one side and 100 on the other.</paragraph>
                  <table width="60%" styleCode="Noautorules">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="right" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottles (opaque plastic) of 100 tablets…</td>
                           <td>
                              <content styleCode="bold">NDC</content> 42858-799-01</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">200 mg </content>- capsule-shaped, green-colored, film-coated tablets bearing the symbol PF on one side and M 200 on the other.</paragraph>
                  <table width="60%" styleCode="Noautorules">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="right" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottles (opaque plastic) of 100 tablets…</td>
                           <td>
                              <content styleCode="bold">NDC</content> 42858-900-01</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20231227"/>
               <component>
                  <section>
                     <id root="2f842deb-8063-4801-8d59-6dc1c83ef1f6"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 25°C (77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</paragraph>
                        <paragraph>Store MS CONTIN securely and dispose of properly <content styleCode="italics">[see <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]</content>.</paragraph>
                        <paragraph>Dispense in a tight, light-resistant container.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="57921ee6-9ceb-40b7-bcef-a3629dc1ddb1"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
               </text>
               <effectiveTime value="20231227"/>
               <component>
                  <section>
                     <id root="6a00467c-a663-4212-ac88-905e8c255b58"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Disposal</content>
                        </paragraph>
                        <paragraph>Because of the risks associated with accidental ingestion, misuse, and abuse, advise patients to store MS CONTIN securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home. Inform patients that leaving MS CONTIN unsecured can pose a deadly risk to others in the home <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S9.2">Drug Abuse and Dependence (9.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise patients and caregivers that when medicines are no longer needed, they should be disposed of promptly. Expired, unwanted, or unused MS CONTIN should be disposed of by flushing the unused medication down the toilet if a drug take-back option is not readily available. Inform patients that they can visit <content styleCode="underline">www.fda.gov/drugdisposal</content> for a complete list of medicines recommended for disposal by flushing, as well as additional information on disposal of unused medicines.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5f4051ea-35a5-4b18-b900-350368f14b37"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Addiction, Abuse, and Misuse</content>
                        </paragraph>
                        <paragraph>Inform patients that the use of MS CONTIN, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. Instruct patients not to share MS CONTIN with others and to take steps to protect MS CONTIN from theft or misuse.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="07edd08c-9a9a-48b5-8af7-139b4510f2fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Life-Threatening Respiratory Depression</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting MS CONTIN or when the dosage is increased, and that it can occur even at recommended dosages.</paragraph>
                        <paragraph>Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, <linkHtml href="#S10">Overdosage (10)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7818a841-6116-428b-b8ea-a330e275d871"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Accidental Ingestion</content>
                        </paragraph>
                        <paragraph>Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8a7ee429-892f-458f-94e7-2b076faeee9d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Interactions with Benzodiazepines and Other CNS Depressants</content>
                        </paragraph>
                        <paragraph>Inform patients and caregivers that potentially fatal additive effects may occur if MS CONTIN is used with benzodiazepines or other CNS depressants, including alcohol, and not to use these concomitantly unless supervised by a healthcare provider <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="79ad6141-2081-4be4-adc1-193cf94da3c9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose</content>
                        </paragraph>
                        <paragraph>Discuss with the patient and caregiver the availability of naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with MS CONTIN. Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Educate patients and caregivers on how to recognize the signs and symptoms of an overdose.</paragraph>
                        <paragraph>Explain to patients and caregivers that naloxone's effects are temporary, and that they must call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>If naloxone is prescribed, also advise patients and caregivers:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>How to treat with naloxone in the event of an opioid overdose</item>
                           <item>To tell family and friends about their naloxone and to keep it in a place where family and friends can access it in an emergency</item>
                           <item>To read the Patient Information (or other educational material) that will come with their naloxone. Emphasize the importance of doing this before an opioid emergency happens, so the patient and caregiver will know what to do.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="fa19467b-ebdb-4ce9-af7b-72acc5ab59b0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hyperalgesia and Allodynia</content>
                        </paragraph>
                        <paragraph>Inform patients and caregivers not to increase opioid dosage without first consulting a clinician. Advise patients to seek medical attention if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>, <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f386de57-455d-45dc-b5e2-ba74acc32da7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serotonin Syndrome</content>
                        </paragraph>
                        <paragraph>Inform patients that opioids could cause a rare but potentially life-threatening condition called serotonin syndrome resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their physicians if they are taking, or plan to take serotonergic medications <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions 7</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="86baf189-bbd0-48f6-99ed-20e3ea8c1018"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">MAOI Interaction</content>
                        </paragraph>
                        <paragraph>Inform patients not to take MS CONTIN while using any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking MS CONTIN <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="14c0a5ac-1f2d-4ca8-a4cb-18f539dfb35e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Important Administration Instructions</content>
                        </paragraph>
                        <paragraph>Instruct patients how to properly take MS CONTIN, including the following:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Swallow MS CONTIN tablets whole <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>
                           </item>
                           <item>Do not crush, chew, or dissolve the tablets <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>
                           </item>
                           <item>Use MS CONTIN exactly as prescribed to reduce the risk of life-threatening adverse reactions (e.g., respiratory depression) <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5bfc263c-75fb-42a4-9a9a-89005157be24"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Important Discontinuation Instructions</content>
                        </paragraph>
                        <paragraph>In order to avoid developing withdrawal symptoms, instruct patients not to discontinue MS CONTIN without first discussing a tapering plan with the prescriber <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bd764cca-376b-4bbf-8a64-6bc7983fcbc6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Driving or Operating Heavy Machinery</content>
                        </paragraph>
                        <paragraph>Inform patients that MS CONTIN may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication <content styleCode="italics">[see <linkHtml href="#S5.15">Warnings and Precautions (5.15</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0a044822-d206-4b5d-b0ec-38f4967834f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Constipation</content>
                        </paragraph>
                        <paragraph>Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>, <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="de08ce9b-8629-41da-adf5-f0aa59cc8411"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adrenal Insufficiency</content>
                        </paragraph>
                        <paragraph>Inform patients that MS CONTIN could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b4a20179-3121-45e0-b783-b5b649160a1c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypotension</content>
                        </paragraph>
                        <paragraph>Inform patients that MS CONTIN may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position) <content styleCode="italics">[see <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32fb1a45-0641-4088-bdeb-4a743d52f2a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Anaphylaxis</content>
                        </paragraph>
                        <paragraph>Inform patients that anaphylaxis has been reported with ingredients contained in MS CONTIN. Advise patients how to recognize such a reaction and when to seek medical attention <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d813b82b-a309-49c3-8517-e49b7106f018"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                     <component>
                        <section>
                           <id root="c552670e-694d-4b71-ab11-cf5cd87d733d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Neonatal Opioid Withdrawal Syndrome</content>
                              </paragraph>
                              <paragraph>Inform female patients of reproductive potential that use of MS CONTIN for an extended period of time during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life- threatening if not recognized and treated <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="661eae02-9c22-4d5d-ad5c-c4f63bb90208"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Embryo-Fetal Toxicity</content>
                              </paragraph>
                              <paragraph>Inform female patients of reproductive potential that MS CONTIN can cause fetal harm and to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20231227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7258c337-6704-428d-8945-c8f27c2b6758"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise patients that breastfeeding is not recommended during treatment with MS CONTIN <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bc35786b-ceb8-4645-b605-e81c67e780fd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Inform patients that chronic use of opioids may cause reduced fertility. It is not known whether these effects on fertility are reversible <content styleCode="italics">[Use in Specific Populations (8.3)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="84775b70-6c3d-4c47-890b-13cbadfe114e"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Healthcare professionals can telephone Rhodes Pharmaceuticals L.P.'s Medical Services Department (1-888-827-0616) for information on this product.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                     <br/>Purdue Pharma L.P.<br/>Stamford, CT 06901-3431</paragraph>
                  <paragraph>
                     <content styleCode="bold">Marketed by:</content>
                     <br/>Rhodes Pharmaceuticals,<br/> Wilson, NC 27893</paragraph>
                  <paragraph>xxxxxxx-0x</paragraph>
                  <paragraph>Revised 12/2023</paragraph>
               </text>
               <effectiveTime value="20231227"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2372777a-9091-4bf4-adbf-225b8fd730ad"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="50%" align="left" valign="top"/>
                     <col width="30%" align="left" valign="top"/>
                     <col width="20%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" colspan="3">Medication Guide<br/>MS CONTIN<sup>®</sup> (MS-KON-tin) (morphine sulfate extended-release tablets), CII</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" valign="top" colspan="2">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right" valign="top">Revised: 12/2023</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">MS CONTIN is:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage severe and persistent pain that required an extended treatment period with a daily opioid pain medicine, when other pain medicines do not treat your pain well enough or you cannot tolerate them.</item>
                                 <item>A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.</item>
                                 <item>Not to be taken on an "as needed" basis.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">Important information about MS CONTIN:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Get emergency help or call 911 right away if you take too much MS CONTIN (overdose)</content>. When you first start taking MS CONTIN, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.</item>
                                 <item>Taking MS CONTIN with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.</item>
                                 <item>Never give anyone else your MS CONTIN. They could die from taking it. Selling or giving away MS CONTIN is against the law.</item>
                                 <item>Store MS CONTIN securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">Do not take MS CONTIN if you have:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>severe asthma, trouble breathing, or other lung problems.</item>
                                 <item>a bowel blockage or have narrowing of the stomach or intestines.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">Before taking MS CONTIN, tell your healthcare provider if you have a history of:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Head injury, seizures</item>
                                 <item>problems urinating</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>liver, kidney, thyroid problems</item>
                                 <item>pancreas or gallbladder problems</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="left" styleCode="Lrule Rrule" colspan="3">
                              <list listType="unordered" styleCode="Disc">
                                 <item>abuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problems.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">Tell your healthcare provider if you are:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Noticing your pain getting worse</content>. If your pain gets worse after you take MS CONTIN, do not take more of MS CONTIN without first talking to your healthcare provider. Talk to your healthcare provider if the pain you that have increases, if you feel more sensitive to pain, or if you have new pain after taking MS CONTIN.</item>
                                 <item>
                                    <content styleCode="bold">Pregnant or planning to become pregnant.</content>  Use of MS CONTIN for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life- threatening if not recognized and treated.</item>
                                 <item>
                                    <content styleCode="bold">Breastfeeding.</content> Not recommended during treatment with MS CONTIN. It may harm your baby.</item>
                                 <item>Living in a household where there are small children or someone who has abused street or prescription drugs.</item>
                                 <item>Taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking MS CONTIN with certain other medicines can cause serious side effects.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">When taking MS CONTIN:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Do not change your dose. Take MS CONTIN exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest duration.</item>
                                 <item>Take your prescribed dose every 8 to 12 hours, as directed by your healthcare provider. Do not take more than your prescribed dose. If you miss a dose, take your next dose at the usual time.</item>
                                 <item>Swallow MS CONTIN whole. Do not cut, break, chew, crush, dissolve, snort, or inject MS CONTIN because this may cause you to overdose and die.</item>
                                 <item>
                                    <content styleCode="bold">Call your healthcare provider if the dose you are taking does not control your pain.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not stop taking MS CONTIN without talking to your healthcare provider.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Dispose of expired, unwanted, or unused MS CONTIN by promptly flushing down the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">While taking MS CONTIN DO NOT:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Drive or operate heavy machinery, until you know how MS CONTIN affects you. MS CONTIN can make you sleepy, dizzy, or lightheaded.</item>
                                 <item>Drink alcohol or use prescription or over-the-counter medicines that contain alcohol.  Using products containing alcohol during treatment with MS CONTIN may cause you to overdose and die.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">The possible side effects of MS CONTIN are:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold">Get emergency medical help or call  911 right away if you have:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion. </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="3">These are not all the possible side effects of MS CONTIN.  Call your healthcare provider for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088. <content styleCode="bold">For more information, go to dailymed.nlm.nih.gov.</content>
                              <br/> Manufactured by:  Purdue Pharma L.P., Stamford, CT 06901-3431, www.purduepharma.com or call 1-888-726-7535<br/>Marketed by: Rhodes Pharmaceuticals, Wilson, NC 27893 US, http://rhodespharma.com, or call 1-888-827-0616.</td>
                        </tr>
                        <tr>
                           <td/>
                           <td/>
                           <td/>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20231227"/>
            </section>
         </component>
         <component>
            <section>
               <id root="39863767-32f9-4a7f-94ac-621ea2330409"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 15 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Attention Dispenser: </content>Accompanying<br/>Medication Guide must be provided to<br/>the patient upon dispensing.</paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC </content>42858-<content styleCode="bold">515</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">MS Contin</content>
                     <sup>®</sup>
                     <br/>(morphine sulfate<br/>extended-release tablets)</paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">15 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rhodes</content>
                  </paragraph>
                  <paragraph>R<sub>x</sub> Only</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20231227"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 15 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ms-contin-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="17ca6497-9e02-4e90-a42d-64a8e6b091d2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Attention Dispenser: </content>Accompanying<br/>Medication Guide must be provided to<br/>the patient upon dispensing.</paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC </content>42858-<content styleCode="bold">631</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">MS Contin</content>
                     <sup>®</sup>
                     <br/>(morphine sulfate<br/>extended-release tablets)</paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rhodes</content>
                  </paragraph>
                  <paragraph>R<sub>x</sub> Only</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20231227"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ms-contin-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="deb073e5-4259-4994-8fe4-2a0122fcb867"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 60 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Attention Dispenser: </content>Accompanying<br/>Medication Guide must be provided to<br/>the patient upon dispensing.</paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC </content>42858-<content styleCode="bold">760</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">MS Contin</content>
                     <sup>®</sup>
                     <br/>(morphine sulfate<br/>extended-release tablets)</paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rhodes</content>
                  </paragraph>
                  <paragraph>R<sub>x</sub> Only</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20231227"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 60 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ms-contin-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2de16bfe-949f-449e-a7f3-f905a7906841"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Attention Dispenser: </content>Accompanying<br/>Medication Guide must be provided to<br/>the patient upon dispensing.</paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC </content>42858-<content styleCode="bold">799</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">MS Contin</content>
                     <sup>®</sup>
                     <br/>(morphine sulfate<br/>extended-release tablets)</paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rhodes</content>
                  </paragraph>
                  <paragraph>R<sub>x</sub> Only<br/>100 Tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">for use in opioid-<br/>tolerant patients<br/>only</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20231227"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ms-contin-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="04f522eb-e37c-487a-8df0-999b2e6e5a57"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Attention Dispenser: </content>Accompanying<br/>Medication Guide must be provided to<br/>the patient upon dispensing.</paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC </content>42858-<content styleCode="bold">900</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">MS Contin</content>
                     <sup>®</sup>
                     <br/>(morphine sulfate<br/>extended-release tablets)</paragraph>
                  <paragraph>
                     <content styleCode="bold">CII</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">200 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rhodes</content>
                  </paragraph>
                  <paragraph>R<sub>x</sub> Only<br/>100 Tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">for use in opioid-<br/>tolerant patients<br/>only</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20231227"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ms-contin-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>